Document is current
Any future updates will be listed below
-
Authors
Spring, Laura M.
Scarpetti, Lauren
Medford, Arielle J.
Niemierko, Andrzej
Comander, Amy https://orcid.org/0000-0002-1644-9297
Mulvey, Therese
Schnipper, Lowell
Isakoff, Steven J. https://orcid.org/0000-0002-6677-1014
Moy, Beverly https://orcid.org/0000-0003-3472-1140
Wander, Seth A. https://orcid.org/0000-0002-4127-4708
Shin, Jennifer
Ephrem, Zanta
Laposta, Anneke R.
Denault, Elyssa
Abraham, Elizabeth
Calistro, Gayle
Kalashnikova, Ekaterina
Rodriguez, Angel
Liu, Minetta C. https://orcid.org/0000-0002-8206-5232
Aleshin, Alexey
Peppercorn, Jeffrey
Ellisen, Leif W. https://orcid.org/0000-0003-0444-7910
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12CA087723)
- License Information
-
More Information
Article History
Received: 25 August 2023
Accepted: 6 November 2024
First Online: 7 January 2025
Competing interests
: Author LMS declares the following relationships: Consultant/advisory board: Novartis, Puma, G1 therapeutics, Daiichi Pharma, Astra Zeneca; Institutional research support: Phillips, Merck, Genentech, Gilead, Eli Lilly. Author SJI declares the following relationships: Consultant/advisory board: Novartis. Author SAW declares the following relationships: Consultant/advisory board: Foundation Medicine, Veracyte, Hologic, Pfizer, Biovica, Guardant Health, Eli Lilly; Institutional research support: Genentech, Eli Lilly, Nuvation Bio, Regor Therapeutics. Author AB declares the following relationships: Consultant/advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Pharma/Astra Zeneca, Puma, Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine; Contracted research/grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Daiichi Pharma/Astra Zeneca. Authors LS, AJM, AN, AC, TM, LS, BM, JS, ZE, ARL, ED, EA, GC, EK, AR, MCL, AA, JP, LWE declare no financial or non-financial competing interests.
